Matthew Galsky

Academic / Other · 12 registered clinical trials — 1 currently recruiting.

Status	Trial	Phase	Started
Recruiting	Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Muscle Invasive Bladder Urothelial Carcinoma	Phase 2	2025-04-07
Active Not Recruiting	Pembrolizumab in Muscle-invasive Bladder Cancer Muscle Invasive Bladder Carcinoma, Localized Cancer, Urothelial Carcinoma	Phase 2	2022-07-13
Completed	Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer Urothelial/Bladder Cancer, Nos	Phase 1	2019-05-08
Completed	Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer Urothelial Carcinoma	Phase 2	2018-11-12
Completed	Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Bladder Cancer	Phase 2	2018-07-13
Completed	Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Pat Metastatic Urothelial Cancer	Phase 2	2018-05-10
Completed	Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations Metastatic Urothelial Cancer	Phase 2	2018-04-17
Completed	Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladd Urothelial Carcinoma, Bladder Cancer	Phase 2	2015-11-11
Completed	Metformin for Rising PSA Remote Trial Prostate Cancer	N/A	2014-07-01
Terminated	Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tum Solid Tumors, Bladder Cancer	Phase 1	2012-01-01
Terminated	Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma Bladder Cancer	Phase 2	2011-02-01
Terminated	First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Transitional Cell Carcinoma, Bladder Carcinoma, Urothelial Carcinoma	Phase 2	2010-12-01